{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:20:17Z","timestamp":1764588017632,"version":"3.46.0"},"reference-count":96,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.1080\/13543776.2025.2575028","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:10:03Z","timestamp":1760415003000},"page":"1185-1207","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Medicinal chemistry perspective of ERK1\/2 inhibitors in cancer treatment: an updated patent review (2019\u2013present)"],"prefix":"10.1080","volume":"35","author":[{"given":"Ankit Kumar","family":"Singh","sequence":"first","affiliation":[{"name":"Central University of Punjab","place":["Bathinda, India"]},{"name":"Sam Higginbottom University of Agriculture, Technology and Sciences","place":["Prayagraj, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajad","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Central University of Punjab","place":["Bathinda, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineet","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Central University of Punjab","place":["Bathinda, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adarsh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Central University of Punjab","place":["Bathinda, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshwardhan","family":"Singh","sequence":"additional","affiliation":[{"name":"Central University of Punjab","place":["Bathinda, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-7335","authenticated-orcid":false,"given":"Amita","family":"Verma","sequence":"additional","affiliation":[{"name":"Sam Higginbottom University of Agriculture, Technology and Sciences","place":["Prayagraj, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Kumar","sequence":"additional","affiliation":[{"name":"Central University of Punjab","place":["Bathinda, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.035"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871520622666220624164152"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2019.02.076"},{"key":"e_1_3_6_5_1","first-page":"29","article-title":"Targeted therapies in melanoma: successes and pitfalls","volume":"7","author":"Palmieri G","year":"2013","unstructured":"Palmieri G, Colombino M, Sini MC, et al. Targeted therapies in melanoma: successes and pitfalls. Melanoma Early Detect Treat. 2013:7 29\u201358.","journal-title":"Melanoma Early Detect Treat"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.010"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.3"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c00332"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123026"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.05.010"},{"key":"e_1_3_6_11_1","first-page":"ISBN: 978-1-780","article-title":"Melanoma pathophysiology and drug targets","author":"Palmieri G","year":"2012","unstructured":"Palmieri G, Rozzo C, Gentilcore G, et al. Melanoma pathophysiology and drug targets. Future Med. 2012 ISBN: 978-1-78084-032\u20131.","journal-title":"Future Med"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2007.apm_855.xml.x"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/423239"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1039\/D3MD00145H"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-01552-6"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00554-5"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-008-9089-1"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2297-8"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.05.006"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0687"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/jbiol46"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.02.007"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2019.1648477"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.10.002"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161212800672813"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0456"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.8b00220"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00389"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0554"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-4973"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061483"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-5168"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01295"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-3760"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.12.022"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100350"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101991"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1119"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01326-3"},{"key":"e_1_3_6_40_1","unstructured":"Sharp Merck A study of the safety tolerability and efficacy of MK-8353 in participants with advanced solid tumors (MK-8353\u2013001). 2011 NCT01358331."},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92352"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.4103\/JIPO.JIPO_17_18"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2574"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.2577"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e15088"},{"key":"e_1_3_6_46_1","unstructured":"Eli Lilly and Company. A study of LY3214996 administered alone or in combination with other agents in participants with advanced\/metastatic cancer 2022."},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3640"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.1c00113"},{"key":"e_1_3_6_49_1","unstructured":"Schram AM First-in-human study of KO-947 in non-hematological malignancies. 2024."},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0002"},{"key":"e_1_3_6_51_1","unstructured":"BioSciences Asana A study of ASN007 in patients with advanced solid tumors. 2024."},{"key":"e_1_3_6_52_1","unstructured":"Zhang J Xu W Jian S Inventors; Changzhou Jiekai Pharmatech Co. Ltd. assignee. Heterocyclic compounds as ERK inhibitors. US10479791B2. 2019."},{"key":"e_1_3_6_53_1","unstructured":"Berdini V Maria Buck I Edward Harvey Day J et al. Inventors; Otsuka Pharmaceutical Co. Ltd. assignee. Benzolactam compounds as protein kinase inhibitors. US20190047990A1. 2019"},{"key":"e_1_3_6_54_1","unstructured":"Yi L Ning L Tao Y et al. Inventors; Medshine Discovery Inc. assignee. Thiazololactam compound as ERK inhibitor and use thereof. WO2021110169A1. 2021."},{"key":"e_1_3_6_55_1","unstructured":"Yi L Ning L Tao Y et al. Inventors; Medshine Discovery Inc. assignee. Spiro compound serving as ERK inhibitor and application thereof. WO2021110168A1. 2021."},{"key":"e_1_3_6_56_1","unstructured":"Thompson SK Smith RA Reddy S et al. Inventors; Asana BioSciences LLC assignee. Quinazolines and azaquinazolines as dual inhibitors of RAS\/RAF\/MEK\/ERK and PI3K\/AKT\/PTEN\/MTOR pathways. US20190151327A1. 2019"},{"key":"e_1_3_6_57_1","unstructured":"Li L Wu T Feng J et al. Inventors; Kura Oncology Inc. assignee. Inhibitors of ERK and methods of use. US20190292194 A1. 2019."},{"key":"e_1_3_6_58_1","unstructured":"Jintao Z Wen X Inventors; JIS-Inda Pharmaceutical Technology Co. Ltd. assignee. Heterocyclic compound kinase inhibitors and pharmaceutical compositions and applications thereof. CN111032656 B. 2022."},{"key":"e_1_3_6_59_1","unstructured":"Singh RK Moore RG Kim K et al. Inventors; University of Rochester assignee. MAPK\/ERK inhibition for ovarian and other cancer. Wo2019183385 a1. 2019."},{"key":"e_1_3_6_60_1","unstructured":"Nadia H Deqiang N Russell C et al. Inventors; Celgene CAR LLC assignee. ERK inhibitors and uses thereof. EP2953457 B1. 2020."},{"key":"e_1_3_6_61_1","unstructured":"Paliwal S Cornwell S Inventors; The Trustees of The Stevens Institute of Technology assignee. ERK inhibitors for cancer therapy. Wo2021216777 a1. 2021."},{"key":"e_1_3_6_62_1","unstructured":"Kotz GS Joseph S Mclean JA et al. Inventors; Eli Lilly & Company assignee. Thieno(2 3-c)pyrrol-4-ones as ERK inhibitors. Cn107108648 b. 2019."},{"key":"e_1_3_6_63_1","unstructured":"Porta DG inventor; Novartis AG assignee. A triple pharmaceutical combination comprising dabrafenib an ERK inhibitor and a SHP2 inhibitor. WO2021171261. 2021 p. A1."},{"key":"e_1_3_6_64_1","unstructured":"Bagdanoff JT Ding Y Han W et al. Inventors; Novartis AG assignee. Aminoheteroaryl benzamides as kinase inhibitors. US10660888 B2. 2020."},{"key":"e_1_3_6_65_1","unstructured":"Zhang J Xu W Jian S Inventors; Changzhou Jiekai Pharmatech Co. Ltd. assignee. Pyrazolo fused heterocyclic compounds as ERK inhibitors. Us10696687 b2. 2020"},{"key":"e_1_3_6_66_1","unstructured":"Reeves CM Oboyle BM Hilf JA et al. Inventors; California Institute of Technology assignee. Erk inhibitors and uses thereof. Wo2020102686 a1. 2020."},{"key":"e_1_3_6_67_1","unstructured":"Wan H Zha C Ma J et al. Inventors; Shanghai Ringene BioPharma Co. Ltd. assignee. Aromatic ring-lactam compound preparation method therefor and use thereof. EP4206199 A1. 2023."},{"key":"e_1_3_6_68_1","unstructured":"Jin L Yonghua L Ming X et al. Inventors; Pharmablock Sciences Inc. assignee. Erk1\/2 protein kinase inhibitor and use thereof. Wo2021063335 a1. 2021."},{"key":"e_1_3_6_69_1","unstructured":"Tongshuang LI Qihong LIU Zhifu LI et al. Inventors; Fochon Biosciences Ltd. assignee. Compounds as ERK inhibitors. Wo2022268065 a1. 2022."},{"key":"e_1_3_6_70_1","unstructured":"Rony S Karen F Xavier BR et al. Inventors; Yeda Research and Development Co. Ltd. assignee. Inhibitors of ERK nuclear translocation. Wo2020115744 a1. 2020."},{"key":"e_1_3_6_71_1","unstructured":"Yungen XU Dezhong JI Lingzhi Z et al. Inventors; China Pharmaceutical University assignee. Erk inhibitor containing isoindole preparation method therefor and application thereof. Wo2020107987 a1. 2020."},{"key":"e_1_3_6_72_1","unstructured":"Reader M Wilsher NE Saunders MH et al. Inventors; Otsuka Pharmaceutical Co. Ltd. assignee. 6-pyrimidin-isoindole derivative as ERK1\/2 inhibitor. US20220169638 A1. 2022."},{"key":"e_1_3_6_73_1","unstructured":"Guichou JF Bories C Geoffroy C et al. Inventors; AGV Discovery assignee. Azaindole derivatives and their use as ERK kinase inhibitors. Us11708364 b2. 2023."},{"key":"e_1_3_6_74_1","unstructured":"Bories C Mathieu L Guichou JF et al. Inventors; AGV Discovery assignee. Azaindole derivatives and their use as ERK kinase inhibitors. US20230227451 A1. 2023."},{"key":"e_1_3_6_75_1","unstructured":"Saha S Welsch D Decrescenzo G et al. Inventors; Biomed Valley Discoveries Inc. assignee. Cancer treatment using combinations of ERK and RAF inhibitors. Us10668055 b2. 2020."},{"key":"e_1_3_6_76_1","unstructured":"Wu H Gu W Tang X et al. Inventors; Betta Pharmaceuticals Co. Ltd. assignee. Erk inhibitor and use thereof. US20210261552 A1. 2020"},{"key":"e_1_3_6_77_1","unstructured":"Deng W Zhai D Rodon L et al. Inventors; Turning Point Therapeutics inc. assignee. Combination therapy involving diaryl macrocyclic compounds. US20210154198 A1. 2021."},{"key":"e_1_3_6_78_1","unstructured":"Xuan D Yang XQ Lin W Inventors; Erasca In. assignee. Uses of heterocyclic inhibitor of ERK1\/2. Wo2022221547 a1. 2022."},{"key":"e_1_3_6_79_1","unstructured":"Reddy S Denis L Rao N et al. Inventors; Asana Biosciences LLC assignee. Improved methods kits composition and dosing regimens for the use of heterocyclic inhibitors of ERK1 and ERK2. US20230027072 A1. 2023."},{"key":"e_1_3_6_80_1","unstructured":"Venkatesan AM Thompson SK Smith RA et al. Inventors; Asana Biosciences LLC assignee. Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer. ES2930050 T3. 2022."},{"key":"e_1_3_6_81_1","unstructured":"Liu X Ding CZ Chen S et al. Inventors; Medshine Discovery Inc. assignee. Compounds containing benzosultam. US20230183230 A1. 2023."},{"key":"e_1_3_6_82_1","unstructured":"Dalby K Edupuganti R Kaoud T et al. Inventors; Board of Regents The University of Texas System assignee. Erk inhibitors. Wo2024187093 a1. 2024."},{"key":"e_1_3_6_83_1","unstructured":"Backos DS Bettendorf TM Cook AW et al. Inventors; Array Biopharma Inc. assignee. Erk protein kinase inhibitors. Wo2024218632 a1. 2024."},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.038"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.05.010"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3979"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184604"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1504_23"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1265137"},{"issue":"17","key":"e_1_3_6_90_1","doi-asserted-by":"crossref","first-page":"A001","DOI":"10.1158\/1538-7445.PANCREATIC24-A001","article-title":"Abstract A001: an open label, phase II trial of ERK inhibition alone and in combination with autophagy inhibition in patients with metastatic pancreatic cancer","volume":"84","author":"Surana R","year":"2024","unstructured":"Surana R, Zheng H, Wang J, et al. Abstract A001: an open label, phase II trial of ERK inhibition alone and in combination with autophagy inhibition in patients with metastatic pancreatic cancer. Cancer Res. 2024;84(17):A001\u2013A001.","journal-title":"Cancer Res"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00754-9"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-023-02592-4"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/ad1c9e"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-LB031"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107207118"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2022.116922"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2019-0339"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2025.2575028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:10:36Z","timestamp":1764587436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2025.2575028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":96,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,2]]}},"alternative-id":["10.1080\/13543776.2025.2575028"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2025.2575028","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"type":"print","value":"1354-3776"},{"type":"electronic","value":"1744-7674"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}